Alnylam Pharmaceuticals Inc ALNY

NAS: ALNY | ISIN: US02043Q1076 3/07/2025

331,91 USD (+0,65%)

(+0,65%) 3/07/2025

Grafiek Alnylam Pharmaceuticals Inc

Grafiek Alnylam Pharmaceuticals Inc

1 dag1d 0,65%
1 week1w 2,81%
1 maand1m 8,71%
3 maanden3m 40,79%
6 maanden6m 42,36%
1 jaar1j 32,22%
5 jaar5j 117,75%

Alnylam Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

30 april 2024 · Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia · Persbericht

3 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY · Persbericht

25 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY · Persbericht

18 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY · Persbericht

9 maart 2023 · Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics · Persbericht

15 september 2022 · Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers · Persbericht

9 december 2021 · Direxion Launches mRNA ETF (MSGR) · Persbericht

Profiel Alnylam Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.alnylam.com

Hoofdzetel: Cambridge, Massachusetts Verenigde Staten

CEO: John Maraganore

Werknemers: 2.246

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe